Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease (Q34384926)

1 August 2017

1 reference

title

Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease (English)

1 reference

1 August 2017

1 reference

1 reference

Huber K

1

1 reference

1 August 2017

1 May 2001

1 reference

Journal of Thrombosis and Thrombolysis

1 August 2017

1 reference

1 August 2017

11

1 reference

1 August 2017

3

1 reference

1 August 2017

183-193

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1011955018052

1 August 2017

0 references

cites work

[Persistent changes in tissue-type plasminogen activator and plasminogen activator inhibitor fibrinolytic parameters in patients following juvenile ischemic cerebral infarct]

1 reference

12 December 2020

Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction

1 reference

12 December 2020

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

1 reference

12 December 2020

Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis

1 reference

12 December 2020

Metformin Causes a Reduction in Basal and Post-venous Occlusion Plasminogen Activator Inhibitor-1 in Type 2 Diabetic Patients

1 reference

12 December 2020

Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression

1 reference

12 December 2020

The adipocyte and hemostatic balance in obesity: studies of PAI-1.

1 reference

12 December 2020

PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level.

1 reference

12 December 2020

Dietary regulation of fibrinolytic factors

1 reference

12 December 2020

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

1 reference

12 December 2020

Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

1 reference

12 December 2020

The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.

1 reference

12 December 2020

Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes

1 reference

12 December 2020

Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction

1 reference

12 December 2020

Hypoxia induces transcription of the plasminogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells

1 reference

12 December 2020

Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease

1 reference

12 December 2020

Role of gender and genetic variance in plasminogen activator inhibitor-1 secretion from human adipose tissue

1 reference

12 December 2020

Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells

1 reference

12 December 2020

Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis

1 reference

12 December 2020

Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis

1 reference

12 December 2020

The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review

1 reference

12 December 2020

Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group.

1 reference

12 December 2020

Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV

1 reference

12 December 2020

Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men

1 reference

12 December 2020

Plasminogen activator inhibitor (PAI-1) in plasma and platelets

1 reference

12 December 2020

Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide

1 reference

12 December 2020

Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss

1 reference

12 December 2020

PAI-1, obesity, insulin resistance and risk of cardiovascular events

1 reference

12 December 2020

The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctu

1 reference

12 December 2020

Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin

1 reference

12 December 2020

4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model of gene-environment interaction

1 reference

12 December 2020

Plasminogen activator inhibitor 1 and atherothrombosis

1 reference

12 December 2020

Chronic thromboembolic pulmonary hypertension: clinical picture and surgical treatment

1 reference

12 December 2020

Cell-associated plasminogen activation: regulation and physiological functions

1 reference

12 December 2020

Fibrinolytic activity in peripheral atherosclerosis in the elderly

1 reference

12 December 2020

Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators

1 reference

12 December 2020

Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension.

1 reference

12 December 2020

Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors

1 reference

12 December 2020

A new life-long hemorrhagic disorder due to excess plasminogen activator

1 reference

12 December 2020

Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men.

1 reference

12 December 2020

Platelets stimulate endothelial cells to synthesize type 1 plasminogen activator inhibitor. Evaluation of the role of transforming growth factor beta

1 reference

12 December 2020

Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease

1 reference

12 December 2020

Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury: a potential progenitor of restenosis

1 reference

12 December 2020

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

1 reference

12 December 2020

Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease

1 reference

12 December 2020

Effects of exercise training on plasminogen activator inhibitor activity

1 reference

12 December 2020

Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction

1 reference

12 December 2020

The role of the fibrinolytic system in deep vein thrombosis

1 reference

12 December 2020

Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities

1 reference

12 December 2020

Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene.

1 reference

12 December 2020

Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension.

1 reference

12 December 2020

Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study

1 reference

12 December 2020

A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1

1 reference

12 December 2020

Predictive value of PAI-1 plasma activity and thallium perfusion imaging for restenosis after percutaneous transluminal angioplasty in clinically asymptomatic patients

1 reference

12 December 2020

Direct effects of gemfibrozil on the fibrinolytic system. Diminution of synthesis of plasminogen activator inhibitor type 1

1 reference

12 December 2020

Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis

1 reference

12 December 2020

Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease

1 reference

12 December 2020

Insulin and PAI-1 levels during oral glucose tolerance test in patients with coronary heart disease

1 reference

12 December 2020

Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli

1 reference

12 December 2020

Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism

1 reference

12 December 2020

Plasminogen activator inhibitor-1 (PAI-1) content in platelets from healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 gene

1 reference

12 December 2020

Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease

1 reference

12 December 2020

The insulin resistance syndrome in smokers is related to smoking habits

1 reference

12 December 2020

Detection of plasminogen activator inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization

1 reference

12 December 2020

Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.

1 reference

12 December 2020

Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters.

1 reference

12 December 2020

Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography.

1 reference

12 December 2020

Attenuation of thrombolysis-induced increase of plasminogen activator inhibitor-1 by intravenous enalaprilat

1 reference

12 December 2020

Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents

1 reference

12 December 2020

Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults

1 reference

12 December 2020

Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states

1 reference

12 December 2020

Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction.

1 reference

12 December 2020

Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein

1 reference

12 December 2020

Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis

1 reference

12 December 2020

Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction

1 reference

12 December 2020

Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis

1 reference

12 December 2020

Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms.

1 reference

12 December 2020

Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease

1 reference

12 December 2020

Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity

1 reference

12 December 2020

Inherited fibrinolytic disorder due to an enhanced plasminogen activator level

1 reference

12 December 2020

Hypertriglyceridemia and regulation of fibrinolytic activity

1 reference

12 December 2020

Diabetes and atherosclerosis: an epidemiologic view

1 reference

12 December 2020

The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells

1 reference

12 December 2020

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

1 reference

12 December 2020

Hypofibrinolysis and insulin-resistance.

1 reference

12 December 2020

The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease

1 reference

12 December 2020

Hyperlipoproteinaemia and Reduced Fibrinolytic Activity in Healthy Coronary High‐Risk Men

1 reference

12 December 2020

The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction

1 reference

12 December 2020

The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.

1 reference

12 December 2020

Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.

1 reference

12 December 2020

Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort.

1 reference

12 December 2020

The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells.

1 reference

12 December 2020

Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly

1 reference

12 December 2020

Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control.

1 reference

12 December 2020

Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease

1 reference

12 December 2020

Fibrinolytic and hemostatic parameter response after resistance exercise

1 reference

12 December 2020

Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function

1 reference

12 December 2020

Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor--relationship to deep vein thrombosis and influence of prophylaxis

1 reference

12 December 2020

Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis

1 reference

12 December 2020

Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1

1 reference

12 December 2020

Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction

1 reference

12 December 2020

Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension

1 reference

12 December 2020

Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation

1 reference

12 December 2020

Circadian variation in the frequency of onset of acute myocardial infarction

1 reference

12 December 2020

Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta

1 reference

12 December 2020

Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects.

1 reference

12 December 2020

Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction

1 reference

12 December 2020

Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study

1 reference

12 December 2020

Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells

1 reference

12 December 2020

Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system

1 reference

12 December 2020

Doxazosin improves insulin sensitivity in hypertensive patients.

1 reference

12 December 2020

Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease

1 reference

12 December 2020

Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals

1 reference

12 December 2020

Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group

1 reference

12 December 2020

Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1)

1 reference

12 December 2020

Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction.

1 reference

12 December 2020

Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men.

1 reference

12 December 2020

Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism

1 reference

12 December 2020

Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis

1 reference

12 December 2020

Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes

1 reference

12 December 2020

Plasminogen activator inhibitor in the blood of patients with coronary artery disease

1 reference

12 December 2020

The PAI-1 Gene Locus 4G/5G Polymorphism Is Associated With a Family History of Coronary Artery Disease

1 reference

12 December 2020

Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol

1 reference

12 December 2020

Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.

1 reference

12 December 2020

Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study.

1 reference

12 December 2020

Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension

1 reference

12 December 2020

Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1

1 reference

12 December 2020

HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells

1 reference

12 December 2020

Stimulation by Proinsulin of Expression of Plasminogen Activator Inhibitor Type-I in Endothelial Cells

1 reference

12 December 2020

Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors

1 reference

12 December 2020

Hypercoagulability and Reduced Fibrinolysis in Hyperlipidemia: Relationship to the Metabolic Cardiovascular Syndrome

1 reference

12 December 2020

Rapid inactivation of the plasminogen-activator inhibitor upon secretion from cultured human endothelial cells

1 reference

12 December 2020

Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy

1 reference

12 December 2020

Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease

1 reference

12 December 2020

Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, epiaortic and peripheral occlusive artery disease

1 reference

12 December 2020

Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease

1 reference

12 December 2020

Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells

1 reference

12 December 2020

Comparison of plasminogen activator inhibitor-1 concentration in insulin-resistant versus insulin-sensitive healthy women.

1 reference

12 December 2020

Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop.

1 reference

12 December 2020

The activation of plasminogen activator inhibitor-1 expression by IL-1beta is attenuated by estrogen in hepatoblastoma HepG2 cells expressing estrogen receptor alpha

1 reference

12 December 2020

Insulin resistance and coronary heart disease

1 reference

12 December 2020

Effects of gemfibrozil on lipids and haemostasis after myocardial infarction

1 reference

12 December 2020

Calcium-dependent stabilization of type I plasminogen activator inhibitor within platelet alpha-granules

1 reference

12 December 2020

A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency

1 reference

12 December 2020

Plasminogen Activator Inhibitor-1 (PAI-1) Antigen Plasma Levels in Subjects Attending a Metabolic Ward: Relation to Polymorphisms of PAI-1 and Angiontensin Converting Enzyme (ACE) Genes

1 reference

12 December 2020

Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.

1 reference

12 December 2020

Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension.

1 reference

12 December 2020

Plasma lipoprotein(a) levels in subjects attending a metabolic ward. Discrimination between individuals with and without a history of ischemic stroke

1 reference

12 December 2020

Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.

1 reference

12 December 2020

Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease

1 reference

12 December 2020

Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension

1 reference

12 December 2020

Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2

1 reference

12 December 2020

PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants.

1 reference

12 December 2020

1 reference

12 December 2020

Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure

1 reference

12 December 2020

Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction

1 reference

12 December 2020

Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity.

1 reference

12 December 2020

Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene

1 reference

12 December 2020

Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension

1 reference

12 December 2020

Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction

1 reference

12 December 2020

Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction.

1 reference

12 December 2020

A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis

1 reference

12 December 2020

An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels

1 reference

12 December 2020

Incidence of increased plasminogen activator inhibitor in patients with deep venous thrombosis and/or pulmonary embolism

1 reference

12 December 2020

Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1011955018052

1 reference

PubMed ID

11577256

Dimensions Publication ID

1 August 2017

0 references

1 reference

PubMed ID

11577256